Rajat Thawani, Assistant Professor at the Knight Cancer Institute at OHSU, shared a post on LinkedIn:
“Read our manuscript published in the International Association for the Study of Lung Cancer, which discusses a case of successful rechallenge with tarlatamab following two high-grade CRS events, resulting in an exceptional response.
This case raises several important considerations:
- High-grade CRS may not preclude tarlatamab candidacy for every patient
- Rechallenge necessitates structured risk mitigation; this is not a general recommendation
- For patients with limited options in relapsed SCLC, the risk-benefit analysis may justify a carefully managed retrial
- The biology of DLL3-directed T-cell engagers is unique, and CRS patterns differ from those observed in CAR-T therapies.”
Title: Successful Tarlatamab Rechallenge After Recurrent High-Grade CRS in Chromothripsis-Mediated SCLC
Authors: Ryan Cheng, Sarah Reddy, Kendra Gee-Rodriguez, Rogelyn Harlan, Chetan Vakkalagadda, Jeremy Cetnar, Rebecca Silbermann, Richard T. Maziarz, Rajat Thawani
Other Articles Featuring Rajat Thawani on OncoDaily.